Early Phase 1 Kidney Cancer Trial, Recruiting NCT07590310 Sponsor: Peking University Cancer Hospital & Institute Condition: Kidney Cancer
Back to Kidney Cancer

Early Phase 1 Kidney Cancer Trial, Recruiting

NCT07590310
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your blood counts, liver function, kidney function, and blood clotting results must meet certain healthy levels as measured by routine lab tests (confirm with trial site for exact values).
  • Your heart must be functioning normally.
  • You are expected to live for at least 12 weeks or more.
  • You are able and willing to attend follow-up appointments as required.
  • You have at least one tumor area that can be measured using standard imaging guidelines.
  • If you are a woman between 18 and 49 years old who could become pregnant, you must have a negative pregnancy test within 7 days before the study examination.
  • If you could become pregnant or father a child, you must agree to use effective birth control during the study and for 3 months after the examination.
  • Your doctor has recommended a PET/CT scan (a type of detailed body imaging) to help diagnose or stage your cancer.
  • You fully understand the study, are willing to take part, and are able to sign a consent form.

Who may not be able to join:

  • You have serious problems with your liver, kidneys, or blood function.
  • You are planning to become pregnant.
  • You are currently pregnant or breastfeeding.
  • You are unable to lie flat and still for 30 minutes.
  • You do not wish to take part in the study.
  • You have claustrophobia (fear of enclosed spaces) or other mental health conditions that may affect participation.
  • The study doctor believes there is any other reason you should not participate (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: +86 18811177191

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Standardized Uptake Value (SUV) of target or suspected tumor lesions in malignant tumor subjects for 68Ga/18F-CAIX-LT-BCH across imaging time points

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov